Personalized Nutrition and Diagnostic Criteria, including Serum Biomarkers, for Osteosarcopenic Obesity as a Model for Body Composition Assessment and Improvement

Guest Editor:

Prof. Dr. Jasminka Ilich-Ernst
Institute for Successful Longevity,
Florida State University,
Tallahassee, FL 32306, USA

Deadline for manuscript submissions:
closed (31 December 2020)

Message from the Guest Editor

Dear Colleagues,

OSO signifies the simultaneous impairment of bone (osteopenia/osteoporosis), muscle (sarcopenia), and adipose tissue (either as overt obesity, or as ectopic fat in visceral area, or as infiltrated fat into bone and muscle). OSO has been associated with poor diet and various metabolic derangements. Although some dietary recommendations for OSO have been published and some updated diagnostic criteria exist, there are no studies investigating the specific serum biomarkers to identify the simultaneous impairment of bone, muscle, and fat or each of the tissues. Additionaly, there is still no consensus for diagnosis of some of the OSO components, namely, sarcopenic obesity and obesity itself, due to the high heterogeneity of the adipose tissue. Manuscripts should address the potential nutritional impact on osteosarcopenic obesity and possible diagnostic criteria for OSO, including bone, muscle/lean tissue, and/or adipose tisse. The serum biomarkers addressing any of the three tissues are of particular interest.

Prof. Dr. Jasminka Ilich-Ernst
Guest Editor

mdpi.com/si/34731

Special Issue

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us